Ustekinumab improves psoriasis-related gene expression in noninvolved psoriatic skin without inhibition of the antimicrobial response

British Journal of Dermatology

Volumn 168, Issue 5, 2013, Pages 990-998

  Baerveldt, E M ^a   Onderdijk, A J ^a   Kurek, D ^a   Kant, M ^a   Florencia, E F ^a   Ijpma, A S ^a   Van Der Spek, P J ^a   Bastiaans, J ^a   Jansen, P A ^b   Van Kilsdonk, J W J ^b   Laman, J D ^a   Prens, E P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA DEFENSIN 2; C REACTIVE PROTEIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; MESSENGER RNA; NERVE GROWTH FACTOR; PSORIASIN; TRANSCRIPTION FACTOR GATA 3; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED DEATH DOMAIN PROTEIN; USTEKINUMAB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GENE EXPRESSION; HUMAN; LEUKOCYTE COUNT; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; SKIN BIOPSY;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIMICROBIAL CATIONIC PEPTIDES; DERMATOLOGIC AGENTS; FEMALE; GATA3 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-12; INTERLEUKIN-23; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NERVE GROWTH FACTOR; PSORIASIS; RECEPTORS, INTERLEUKIN; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; SKIN; TREATMENT OUTCOME;

EID: 84876960043     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12175     Document Type: Article

References (31)

1. Di Cesare A, Di Meglio P, Nestle FO,. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 2009; 129: 1339-50.
2. Yeilding N, Szapary P, Brodmerkel C, et al. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives. Ann N Y Acad Sci 2011; 1222: 30-9.
3. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-84.
4. Griffiths CE, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362: 118-28.
5. Reddy M, Torres G, McCormick T, et al. Positive treatment effects of ustekinumab in psoriasis: analysis of lesional and systemic parameters. J Dermatol 2010; 37: 413-25.
6. Reddy M, Davis C, Wong J, et al. Modulation of CLA, IL-12R, CD40L, and IL-2Ralpha expression and inhibition of IL-12- and IL-23-induced cytokine secretion by CNTO 1275. Cell Immunol 2007; 247: 1-11.
7. Nograles KE, Zaba LC, Guttman-Yassky E, et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 2008; 159: 1092-102.
8. Gallo RL, Hooper LV,. Epithelial antimicrobial defence of the skin and intestine. Nat Rev Immunol 2012; 12: 503-16.
9. Harder J, Dressel S, Wittersheim M, et al. Enhanced expression and secretion of antimicrobial peptides in atopic dermatitis and after superficial skin injury. J Invest Dermatol 2010; 130: 1355-64.
10. de Jongh GJ, Zeeuwen PL, Kucharekova M, et al. High expression levels of keratinocyte antimicrobial proteins in psoriasis compared with atopic dermatitis. J Invest Dermatol 2005; 125: 1163-73.
11. Hollox EJ, Huffmeier U, Zeeuwen PL, et al. Psoriasis is associated with increased beta-defensin genomic copy number. Nat Genet 2008; 40: 23-5.
12. Jansen PA, Rodijk-Olthuis D, Hollox EJ, et al. Beta-defensin-2 protein is a serum biomarker for disease activity in psoriasis and reaches biologically relevant concentrations in lesional skin. PLoS ONE 2009; 4: e4725.
13. Krueger JG, Li K, Baribaud F, et al. Determining the extent to which clinically effective treatment, ustekinumab or etanercept, reverses the molecular disease profile of psoriatic skin: comparisons of lesional, non-lesional and normal skin. J Invest Dermatol 2010; 130: S1-100.
14. Wolk K, Haugen HS, Xu W, et al. IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. J Mol Med 2009; 87: 523-36.
15. Gudjonsson JE, Ding J, Li X, et al. Global gene expression analysis reveals evidence for decreased lipid biosynthesis and increased innate immunity in uninvolved psoriatic skin. J Invest Dermatol 2009; 129: 2795-804.
16. de Koning HD, Kamsteeg M, Rodijk-Olthuis D, et al. Epidermal expression of host response genes upon skin barrier disruption in normal skin and uninvolved skin of psoriasis and atopic dermatitis patients. J Invest Dermatol 2011; 131: 263-6.
17. Raychaudhuri SP, Jiang WY, Raychaudhuri SK,. Revisiting the Koebner phenomenon: role of NGF and its receptor system in the pathogenesis of psoriasis. Am J Pathol 2008; 172: 961-71.
18. Braff MH, Di Nardo A, Gallo RL,. Keratinocytes store the antimicrobial peptide cathelicidin in lamellar bodies. J Invest Dermatol 2005; 124: 394-400.
19. Oren A, Ganz T, Liu L, Meerloo T,. In human epidermis, beta-defensin 2 is packaged in lamellar bodies. Exp Mol Pathol 2003; 74: 180-2.
20. de Guzman Strong C, Wertz PW, Wang C, et al. Lipid defect underlies selective skin barrier impairment of an epidermal-specific deletion of Gata-3. J Cell Biol 2006; 175: 661-70.
21. Racz E, Kurek D, Kant M, et al. GATA3 expression is decreased in psoriasis and during epidermal regeneration; induction by narrow-band UVB and IL-4. PLoS ONE 2011; 6: e19806.
22. Breternitz M, Flach M, Prassler J, et al. Acute barrier disruption by adhesive tapes is influenced by pressure, time and anatomical location: integrity and cohesion assessed by sequential tape stripping. A randomized, controlled study. Br J Dermatol 2007; 156: 231-40.
23. van der Fits L, van der Wel LI, Laman JD, et al. Psoriatic lesional skin exhibits an aberrant expression pattern of interferon regulatory factor-2 (IRF-2). J Pathol 2003; 199: 107-14.
24. Racz E, Prens EP, Kurek D, et al. Effective treatment of psoriasis with narrow-band UVB phototherapy is linked to suppression of the IFN and Th17 pathways. J Invest Dermatol 2011; 131: 1547-58.
25. Sonnenberg GF, Fouser LA, Artis D,. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat Immunol 2011; 12: 383-90.
26. Otkjaer K, Kragballe K, Funding AT, et al. The dynamics of gene expression of interleukin-19 and interleukin-20 and their receptors in psoriasis. Br J Dermatol 2005; 153: 911-18.
27. Kunz S, Wolk K, Witte E, et al. Interleukin (IL)-19, IL-20 and IL-24 are produced by and act on keratinocytes and are distinct from classical ILs. Exp Dermatol 2006; 15: 991-1004.
28. Raychaudhuri SP, Sanyal M, Weltman H, et al. K252a, a high-affinity nerve growth factor receptor blocker, improves psoriasis: an in vivo study using the severe combined immunodeficient mouse-human skin model. J Invest Dermatol 2004; 122: 812-19.
29. Schwarzbich MA, Gutknecht M, Salih J, et al. The immune inhibitory receptor osteoactivin is upregulated in monocyte-derived dendritic cells by BCR-ABL tyrosine kinase inhibitors. Cancer Immunol Immunother 2012; 61: 193-202.
30. Katagiri K, Imamura M, Kinashi T,. Spatiotemporal regulation of the kinase Mst1 by binding protein RAPL is critical for lymphocyte polarity and adhesion. Nat Immunol 2006; 7: 919-28.
31. Chio II, Sasaki M, Ghazarian D, et al. TRADD contributes to tumour suppression by regulating ULF-dependent p19Arf ubiquitylation. Nat Cell Biol 2012; 14: 625-33.